Advertisement

Research Article Free access | 10.1172/JCI119534

Role of nitric oxide in obesity-induced beta cell disease.

M Shimabukuro, M Ohneda, Y Lee, and R H Unger

Center for Diabetes Research and Gifford Laboratories, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.

Find articles by Shimabukuro, M. in: JCI | PubMed | Google Scholar

Center for Diabetes Research and Gifford Laboratories, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.

Find articles by Ohneda, M. in: JCI | PubMed | Google Scholar

Center for Diabetes Research and Gifford Laboratories, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.

Find articles by Lee, Y. in: JCI | PubMed | Google Scholar

Center for Diabetes Research and Gifford Laboratories, Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.

Find articles by Unger, R. in: JCI | PubMed | Google Scholar

Published July 15, 1997 - More info

Published in Volume 100, Issue 2 on July 15, 1997
J Clin Invest. 1997;100(2):290–295. https://doi.org/10.1172/JCI119534.
© 1997 The American Society for Clinical Investigation
Published July 15, 1997 - Version history
View PDF
Abstract

Here we report that free fatty acid-induced suppression of insulin output in prediabetic Zucker diabetic fatty (ZDF) rats is mediated by NO. When normal islets were cultured in 2 mM FFA, NO production and basal insulin secretion increased slightly. In cultured prediabetic ZDF islets, FFA induced a fourfold greater rise in NO, upregulated mRNA of inducible nitric oxide synthase (iNOS), and reduced insulin output; both nicotinamide and aminoguanidine, which lower NO, prevented the FFA-mediated increase in iNOS mRNA, reduced NO, and minimized the loss of insulin secretion. In vivo nicotinamide or aminoguanidine treatment of prediabetic ZDF rats prevented the iNOS expression in islets and decreased beta cell dysfunction while blocking beta cell destruction and hyperglycemia. We conclude that NO-lowering agents prevent adipogenic diabetes in obese rats.

Version history
  • Version 1 (July 15, 1997): No description
Advertisement
Advertisement